Name | Tuxobertinib |
Description | Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, with KDs of 0.2, 0.76, 13, and 1.2 nM for EGFR, HER2, BLK, and RIPK2, respectively, and exhibits anticancer activity. |
In vivo | BDTX-189 (0-100 mg/kg;?p.o.;?daily for 15 dyas) shows dose-dependent tumor growth inhibition and regression in in athymic nude mice bearing HER2 S310F Ba/F3 allograft tumors.?BDTX-189 (1-50 mg/kg.p.o.;?daily for 15 days) shows dose-dependent tumor growth inhibition and regression in athymic nude mice bearing CUTO-14 PDX tumors that express the EGFR mutation EGFR ASV |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Solubility Information | DMSO : 41.67 mg/mL (74.27 mM), Sonication is recommended.
|
Keywords | Tuxobertinib | RIPkinase | RIPK2 | RIP kinase | oral | oncogene athymic | nude | mutants | mice | insertion | Inhibitor | inhibit | HER2 | HER1 | ErbB-1 | Epidermal growth factor receptor | EGFR | BLK | BDTX189 | BDTX 189 | Ba/F3 | allosteric |
Inhibitors Related | (S)-Afatinib | Tannic acid | Osimertinib | Lidocaine Hydrochloride hydrate | Oditrasertib | Lapatinib | Erlotinib hydrochloride | Erlotinib | Neratinib | Afatinib | Genistein | Gefitinib |
Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |